Eribulin in cancer treatment

Umang Swami, Umang Shah, Sanjay Goel

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

Original languageEnglish (US)
Pages (from-to)5016-5058
Number of pages43
JournalMarine Drugs
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

eribulin
Breast Neoplasms
Neoplasms
Clinical Pharmacology
Anthracyclines
Macrolides
Porifera
United States Food and Drug Administration
Ketones
Non-Small Cell Lung Carcinoma
Microtubules
Sarcoma
Therapeutics
Pharmacokinetics
Clinical Trials

Keywords

  • Breast cancer
  • E7389
  • EMBRACE
  • Eribulin
  • Halaven<sup>™</sup>
  • Halichondrin B
  • Microtubule inhibitor
  • NSC 707389

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Eribulin in cancer treatment. / Swami, Umang; Shah, Umang; Goel, Sanjay.

In: Marine Drugs, Vol. 13, No. 8, 01.08.2015, p. 5016-5058.

Research output: Contribution to journalArticle

Swami, U, Shah, U & Goel, S 2015, 'Eribulin in cancer treatment', Marine Drugs, vol. 13, no. 8, pp. 5016-5058. https://doi.org/10.3390/md13085016
Swami, Umang ; Shah, Umang ; Goel, Sanjay. / Eribulin in cancer treatment. In: Marine Drugs. 2015 ; Vol. 13, No. 8. pp. 5016-5058.
@article{34e506cf873d40ff853fc85f26f5d6ad,
title = "Eribulin in cancer treatment",
abstract = "Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.",
keywords = "Breast cancer, E7389, EMBRACE, Eribulin, Halaven<sup>™</sup>, Halichondrin B, Microtubule inhibitor, NSC 707389",
author = "Umang Swami and Umang Shah and Sanjay Goel",
year = "2015",
month = "8",
day = "1",
doi = "10.3390/md13085016",
language = "English (US)",
volume = "13",
pages = "5016--5058",
journal = "Marine Drugs",
issn = "1660-3397",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Eribulin in cancer treatment

AU - Swami, Umang

AU - Shah, Umang

AU - Goel, Sanjay

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

AB - Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

KW - Breast cancer

KW - E7389

KW - EMBRACE

KW - Eribulin

KW - Halaven<sup>™</sup>

KW - Halichondrin B

KW - Microtubule inhibitor

KW - NSC 707389

UR - http://www.scopus.com/inward/record.url?scp=84940434435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940434435&partnerID=8YFLogxK

U2 - 10.3390/md13085016

DO - 10.3390/md13085016

M3 - Article

C2 - 26262627

AN - SCOPUS:84940434435

VL - 13

SP - 5016

EP - 5058

JO - Marine Drugs

JF - Marine Drugs

SN - 1660-3397

IS - 8

ER -